Location:
Project Number: 8064-32000-061-041-S
Project Type: Non-Assistance Cooperative Agreement
Start Date: Aug 1, 2017
End Date: Jul 31, 2019
Objective:
ARS, PIADC (hereinafter referred to as "Agency") has developed an attenuated Foot-and-Mouth Disease Virus (FMD) vaccine platform lacking the leader sequence and contains specific antigenic markers called FMDVLL3B3D. This virus has been shown to be attenuated with no detectable viral replication, no transmission and no clinical signs in inoculated animals. The tissue and time of collection for back-passage purposes needs to be determined in pigs inoculated by the most susceptible route. This study will identify the tissue distribution of FMDLL3B3D in swine inoculated by two methods previously shown to cause disease in swine with multiple serotypes of FMDV; the intra-dermal heel bulb (IDH) and the intra-oro-pharyngeal (IOP) methods.
Approach:
1. Agency will provide Friedrich-Loeffler Institut (FLI) the vaccine strain FMDVLL3B3D-A24 Cruzeiro.
2. FLI will procure swine which will be inoculated with FMDVLL3B3D-A24 Cruzeio via IDH (group 1) and IOP (group 2) methods.
3. Ante mortem samples will be collected and designated times post inoculation. Animals will be euthanized at pre-established time points and relevant tissues will be collected. All samples will be processed at FLI for virus isolation using LFBK-alpha v beta 6 per described protocols. All samples, pre-clinical and post mortem, will be tested for the presence of infectious virus by virus isolation. Negative samples will be confirmed by real-time RT-PCR.
